Therapy Insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management

@article{Yarchoan2005TherapyIA,
  title={Therapy Insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management},
  author={Robert Yarchoan and Giovanna Tosato and Richard F. Little},
  journal={Nature Clinical Practice Oncology},
  year={2005},
  volume={2},
  pages={406-415}
}
Patients with HIV infection are at an increased risk of a number of malignancies, including Kaposi's sarcoma (KS) and certain B-cell lymphomas. Most of these tumors are caused by oncogenic DNA viruses, including KS-associated herpesvirus and Epstein–Barr virus. HIV contributes to the development of these tumors through several mechanisms, including immunodeficiency, immunodysregulation, and the effects of HIV proteins such as Tat. The development of highly active antiretroviral therapy (HAART… 

Figures and Tables from this paper

Acquired immunodeficiency syndrome—related malignancies in the era of highly active antiretroviral therapy
TLDR
With the development of HAART and improved prevention and treatment of opportunistic infections, an increasing percentage of the deaths in AIDS patients have been from malignancies and strategies for prevention, screening, and therapy remain important areas of research.
Malignancies in HIV-Infected and AIDS Patients.
TLDR
As those malignancies could be the major issue for HIV infection or AIDS in the future, it is expected enhanced investigations, surveillances, and clinical trial for improving the understanding and management for cancers developed in PLWH.
AIDS and associated malignancies
TLDR
Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi's sarcoma, Hodgkin's disease and non-Hodgkin's lymphoma, which accounts for a greater percentage of AIDS defining illness in the US and Europe since the advent of HAART therapy.
Gastrointestinal Malignancies in HIV-infected or Immunosuppressed Patients: Pathologic Features and Review of the Literature
TLDR
The clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
AIDS and associated malignancies
TLDR
Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi's sarcoma, Hodgkin's disease and non-Hodgkin's lymphoma, which accounts for a greater percentage of AIDS defining illness in the US and Europe since the advent of HAART therapy.
Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary?
TLDR
The published data regarding the interactions of HIV, AIDS, and antiretroviral therapy with radiotherapy and implications for the management of malignancies in patients with HIV are reported.
Reversible features of cervical cancer in human immunodeficiency virus infection
TLDR
The fortuitous timeliness of this report is difficult to over emphasize: the emerging health disparities illustrated by the changing epidemiological features of the HIV/AIDS epidemic highlights the need to reassess cervical cancer’s thirdplace conceptual setting in the triad of AIDS-defining cancers.
Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
TLDR
3 patients who experienced severe vinblastine-associated neurotoxicity during concomitant treatment with ritonavirboosted antiretrovirals are reported and the implications for the treatment of patients with HL in the current era of cART are discussed.
Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
  • T. Uldrick, K. Wyvill, R. Yarchoan
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Bvacizumab is tolerated in patients with HIV-KS and has activity in a subset of patients, and overall response rate was 31% (95% CI, 11% to 58.7%).
Cancer prevention in HIV-infected populations.
TLDR
The etiologic agents and pathogenesis of common malignancies in the setting of HIV are described, as well as current evidence for cancer prevention strategies and screening programs are described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 85 REFERENCES
Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy.
TLDR
The effects that HAART has had on acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin's lymphoma (NHL) are addressed and metaanalysis of numerous cohort studies confirmed that the incidence of AIDS-related NHL has decreased.
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
TLDR
Malignant disease has been a major cause of death among HIV-infected patients in industrialized nations since the introduction of HAART and whereas lethal hemopathies and Kaposi sarcoma are associated with advanced immunosuppression, lethal solid tumors can occur in patients with controlled HIV infection.
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.
TLDR
The profile of ARL has changed since the era of HAART, with a lower incidence of systemic and brain ARL, and the prognosis of systemic ARl has improved.
Epidemiology of AIDS-related malignancies an international perspective.
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
TLDR
The results suggest that the improved immune function associated with highly active antiretroviral therapy (HAART) may have led to a shift in pathogenesis away from lymphomas of post-germinal center origin, which have a poor prognosis.
Association of cancer with AIDS-related immunosuppression in adults.
TLDR
Although occurring in overall excess, most non-AIDS-defining cancers do not appear to be influenced by the advancing immunosuppression associated with HIV disease progression.
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
  • L. Ratner, J. Lee, D. Straus
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
Either modified-dose or full-dose CHOP chemotherapy for HIV-NHL, delivered with HAART, is effective and tolerable.
Aids-related malignancies
TLDR
Gaining insight into the epidemiology and mechanisms that underlie AIDS-related cancers has provided a better understanding of cancer immunity and viral oncogenesis.
Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
  • H. Koon, G. Bubley, B. Dezube
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Impatinib mesylate administered orally twice daily for AIDS-related KS results in clinical and histologic regression of cutaneous KS lesions within 4 weeks demonstrate that inhibition of the c-kit and/or PDGF receptors may represent an effective strategy for treating KS.
Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.
TLDR
It is concluded that parenteral zidovudine, ganciclovir, and interleukin 2 is an active combination for AIDS-related central nervous system lymphoma.
...
1
2
3
4
5
...